KVUE

#414
Kenvue Inc.
17.2550 USD
-0.72%
セクター: 生活必需品
ベース: USD
利益通貨: USD
日中レンジ
17.1650
17.2585
1年のレンジ
14.0200
19.1750
1日の変化
-0.72%
月次変化
-1.96%
6か月変化
+14.42%
1年の変化
+14.42%
以前の終値
17.3800
始値
17.2300
Bid
Ask
安値
17.1650
High
17.2585
ボリューム
1 515
チャート全体を表示

Financials

概要 明細書 統計 配当金
期次 年次
  • Market Capitalization 33.0732 B
  • Employee 22 K
  • Founded 2022
  • CEO N/A
  • Website www.kenvue.com
  • Headquarter Delaware, United States
  • FIGI BBG01C79X561
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
22.62
売上高対価格比率
2.19
1株当たり配当金
0.82
配当利回り（％）
4.8

Kenvue Inc

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

ニュース